Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 10/20 | 0.55 |
| ▸ | NPY4R | P50391 | 7/20 | 0.54 |
| ▸ | NPY1R | P25929 | 6/20 | 0.54 |
| ▸ | NPY2R | P49146 | 6/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974829 | 0.93 | F2 (0.52) | TFPIIL23RF2 | |
| SCHEMBL29973963 | 0.93 | F2 (0.52) | TFPIIL23RF2 | |
| SCHEMBL16509135 | 0.92 | IL23R (0.57) | TFPIIL23RNPY4RNPY1RNPY5R | |
| SCHEMBL16509008 | 0.92 | IL23R (0.57) | TFPIIL23RNPY4RNPY1RNPY5R | |
| SCHEMBL16509090 | 0.92 | TFPI (0.60) | TFPIIL23R | |
| SCHEMBL16509000 | 0.90 | TFPI (0.59) | TFPIIL23R | |
| SCHEMBL16508112 | 0.89 | NPY4R (0.62) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL29611492 | 0.87 | NPY4R (0.59) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31060843 | 0.86 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5RF2 | |
| SCHEMBL30918770 | 0.86 | IL23R (0.62) | TFPIIL23RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280109-B2 | Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines | CENTRO DE INMUNOLOGÍA MOLECULAR (CU) | 2025-04-22 | — | — | US | claimed |
| CN-119698285-A | Use of GnRH antagonists for synchronizing follicular wave appearance in mammals | 萨斯喀彻温大学 | 2025-03-25 | — | — | CN | claimed |
| US-20240408033-A1 | CELL-DERIVED NANOVESICLES FOR IN VIVO TRANSPORT AND DELIVERY OF THERAPEUTIC MATERIALS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-12-12 | — | — | US | claimed |
| US-20240181026-A1 | IMMUNOGENIC COMPOSITIONS | MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (AU) | 2024-06-06 | — | — | US | claimed |
| US-20240131152-A1 | NANO-PARTICLES THAT CONTAIN SYNTHETIC VARIANTS OF GM3 GANGLIOSIDE AS ADJUVANTS IN VACCINES | CENTRO DE INMUNOLOGÍA MOLECULAR (CU) | 2024-04-25 | — | — | US | claimed |
| US-20240124560-A1 | HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | claimed |
| US-20240100083-A1 | IMMUNOTHERAPY FOR CANCER | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2024-03-28 | — | — | US | claimed |
| US-11806396-B2 | Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines | CENTRO DE INMUNOLOGÍA MOLECULAR (CU) | 2023-11-07 | — | — | US | claimed |
| CN-116761625-A | cancer immunotherapy | 都柏林圣三一学院 | 2023-09-15 | — | — | CN | claimed |
| CN-116390743-A | Immunogenic compositions | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4192498-A1 | IMMUNOGENIC COMPOSITIONS | Macfarlane Burnet Institute for Medical Research and Public Health Limited (AU) | 2023-06-14 | — | — | EP | claimed |
| EP-3568409-B1 | AGENT FOR PROMOTING ANGIOGENESIS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2022-12-21 | — | — | EP | claimed |
| WO-2022256024-A1 | COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTIONS | MOREHOUSE SCHOOL OF MEDICINE (US) | 2022-12-08 | — | — | WO | claimed |
| EP-4045532-A1 | HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-08-24 | — | — | EP | claimed |
| US-11414462-B1 | Compositions and methods for treating SARS-CoV-2 infections | MOREHOUSE SCHOOL OF MEDICINE (US) | 2022-08-16 | — | — | US | claimed |
| WO-2022027107-A1 | IMMUNOGENIC COMPOSITIONS | MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (AU) | 2022-02-10 | — | — | WO | claimed |
| EP-4749284-A1 | DETERMINATION OF FREE THYROID HORMONE | pes Diagnosesysteme GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| CN-118032966-B | High-sensitivity LC-MS/MS detection method for monitoring blood concentration of human Carrilizumab | 中国医科大学附属第一医院 | 2026-05-19 | — | — | CN | disclosed |
| WO-2022027107-A1 | IMMUNOGENIC COMPOSITIONS | MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (AU) | 2022-02-10 | — | — | WO | disclosed |
| EP-3941937-A2 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | Codiak BioSciences, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |